Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares stood at 9.68 million during the last session, with the company’s beta value hitting 1.84. At the close of trading, the stock’s price was $1.46, to imply a decrease of -10.43% or -$0.17 in intraday trading. The PACB share’s 52-week high remains $6.09, putting it -317.12% down since that peak but still an impressive 20.55% since price per share fell to its 52-week low of $1.16.
Analysts have given a consensus recommendation of Buy for Pacific Biosciences of California Inc (PACB), translating to a mean rating of 2.19. Of 11 analyst(s) looking at the stock, 1 analyst(s) give PACB a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.19.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
After registering a -10.43% downside in the last session, Pacific Biosciences of California Inc (PACB) has traded red over the past five days. The 5-day price performance for the stock is -10.98%, and -9.32% over 30 days. With these gigs, the year-to-date price performance is -20.22%.
The extremes give us $2 and $4 for target low and target high price respectively. As such, PACB has been trading -173.97% off suggested target high and -36.99% from its likely low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
The rating firms project that company’s revenue will grow 5.07% compared to the previous financial year.
Revenue forecast for the current quarter as set by 12 analysts is 33.66M. Meanwhile, for the current quarter, a total of 12 analyst(s) estimate revenue growth to 38.09M.Earnings reports from the last fiscal year show that sales brought in 38.81M and 36.01M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -13.26% before jumping 5.78% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -15.31% for the past 5-year period. While 2025 is set for a 33.82% return in earnings, projections for the next 5 years are at 24.02% annually.
PACB Dividends
Pacific Biosciences of California Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 26.0 million shares, or about 9.6443% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $35.62 million.
We also have ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Pacific Biosciences of California Inc (PACB) shares. Going by data provided on Dec 31, 2024 , ARK ETF Tr-ARK Innovation ETF holds roughly 21.16 shares. This is just over 7.73% of the total shares, with a market valuation of $30.89 million. Data from the same date shows that the other fund manager holds a little less at 12.14, or 4.43% of the shares, all valued at about 17.72 million.
